Table 1.
Baseline characteristics of patients
| Clear cell mRCC patients (N = 27) | |
|---|---|
| Age, years | 65 (59/69) |
| Male sex, N (%) | 18 (67) |
| Fuhrman | |
| Grade 1–2, N (%) | 10 (37) |
| Grade 3–4, N (%) | 17 (63) |
| Nephrectomy (total or nephron sparing), N (%) | 27 (100) |
| Time from diagnosis to systemic treatment <1 year, N (%) | 14 (52) |
| ECOG performance score | |
| 0, N (%) | 13 (48) |
| 1, N (%) | 13 (48) |
| 2, N (%) | 1 (4) |
| MSKCC prognosis | |
| Favorable, N (%) | 8 (30) |
| Intermediate, N (%) | 19 (70) |
| Metastases | |
| No metastases | 5 (19) |
| Lung, N (%) | 16 (59) |
| Liver, N (%) | 11 (41) |
| Bone, N (%) | 5 (19) |
| 1 Site, N (%) | 15 (56) |
| 2 or more sites, N (%) | 7 (26) |